2010
DOI: 10.1158/1538-7445.am10-5418
|View full text |Cite
|
Sign up to set email alerts
|

Abstract 5418: The immunomodulatory drug lenalidomide restores a Vitamin D sensitive phenotype to the Vitamin D resistant breast cancer cell line MDA-MB-231: Potential for breast cancer therapeutics

Abstract: 1α,25-Dihydroxyvitamin D3, (1,25 D3) the biologically active form of vitamin D, is well established as an inhibitor of cancer cell growth in addition to its primary role in maintaining bone mineralization. In breast cancer cell lines, inhibitory effects on cell cycle arrest, angiogenesis, invasion and metastasis have been observed in addition to pro-apoptotic effects. 1,25 D3 also inhibits and prevents breast cancer growth in several mouse models, and a correlation between vitamin D receptor expression on brea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2010
2010
2012
2012

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…In a vitamin D-resistant breast cancer cell line (MDA-MB-231), a 50 % inhibition of cell growth by biologically active vitamin D (a,25-dihydroxyvitamin D3; 1,25 D3) was achieved in the presence of lenalidomide [67]. The combination of 1,25 D3 and lenalidomide resulted in an increase in pro-apoptotic protein expression leading to inhibition of cell viability and growth [67].…”
Section: Breast Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…In a vitamin D-resistant breast cancer cell line (MDA-MB-231), a 50 % inhibition of cell growth by biologically active vitamin D (a,25-dihydroxyvitamin D3; 1,25 D3) was achieved in the presence of lenalidomide [67]. The combination of 1,25 D3 and lenalidomide resulted in an increase in pro-apoptotic protein expression leading to inhibition of cell viability and growth [67].…”
Section: Breast Cancermentioning
confidence: 99%
“…The combination of 1,25 D3 and lenalidomide resulted in an increase in pro-apoptotic protein expression leading to inhibition of cell viability and growth [67].…”
Section: Breast Cancermentioning
confidence: 99%